Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is expected to announce its earnings results on Wednesday, January 29th. Analysts expect the company to announce earnings of $0.19 per share and revenue of $975,712.23 billion for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Dr. Reddy's Laboratories Price Performance
RDY traded up $0.26 during midday trading on Wednesday, reaching $15.06. 3,461,539 shares of the company's stock were exchanged, compared to its average volume of 2,335,888. Dr. Reddy's Laboratories has a one year low of $13.52 and a one year high of $16.89. The firm has a market capitalization of $12.57 billion, a price-to-earnings ratio of 24.05 and a beta of 0.51. The business has a 50-day simple moving average of $14.86 and a two-hundred day simple moving average of $15.54. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. Barclays dropped their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. Finally, StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th.
Check Out Our Latest Stock Report on Dr. Reddy's Laboratories
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Articles
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
